In detail, both vismodegib and sonidegib significantly (two-fold difference and p < 0.05 NBCCS-HFs-treated vs. untreated) counteract deregulation of IL1α, IL1β, IL18, HGF, A2M (by decreasing), CES1 and WIF1 (by increasing) in NBCCS-HFs (Table 2 and Figure 4) that, however, resulted still significantly higher compared to healthy fibroblasts. This evidence concerns the gene WIF1 and Hand-foot syndrome.